Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radio Salil is a topical analgesic and rubefacient combination product developed and marketed by Laboratorios Viñas. It is indicated for the local symptomatic relief of muscle and joint pain, including conditions such as lumbago, torticollis, strains, and sprains. The formulation typically comprises methyl salicylate, menthol, salicylic acid, camphor, and methyl nicotinate. These components work through multiple mechanisms: methyl salicylate and salicylic acid inhibit cyclooxygenase enzymes to reduce prostaglandin-mediated inflammation and pain; menthol and camphor act as counter-irritants by stimulating thermal receptors (TRPM8 and TRPV1, respectively); and methyl nicotinate induces local vasodilation (rubefacient effect), which enhances blood flow to the affected area and promotes a warming sensation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Radio Salil.